Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9225656 | Journal of Allergy and Clinical Immunology | 2005 | 7 Pages |
Abstract
Once-daily oral roflumilast modestly attenuated early asthmatic reactions and, to a greater extent, LARs to allergen in patients with mild allergic asthma. Pronounced suppression of late responses in an allergen challenge model suggests that roflumilast might have anti-inflammatory activity, which could provide clinical efficacy in chronic inflammatory pulmonary diseases, such as asthma.
Keywords
ICSPC20FEV1PDE4AHRAUCcAMPCyclic adenosine monophosphateAsthmainflammationCOPDChronic obstructive pulmonary diseaseAllergen provocationRoflumilastphosphodiesterase type 4LarLate phasearea under the curveLate asthmatic reactionEarly asthmatic reactionAirway hyperresponsivenessInhaled corticosteroidEAR
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Emmerentia MBChB, K. MBChB, Zelda RN, Louis MSc, Stefan PhD, Christine PhD, Dirk MD, Philip G. FRACP, PhD,